We are live on ! Find out more
SPRY icon

ARS Pharmaceuticals
SPRY

72 hedge funds and large institutions have $200M invested in ARS Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 27 increasing their positions, 18 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 18

3.35% more ownership

Funds ownership: 82.46% → 85.81% (+3.4%)

5% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 20

3% less funds holding

Funds holding: 74 → 72 (-2)

30% less capital invested

Capital invested by funds: $287M → $200M (-$87M)

Holders
72
Holders Change
-2
Holders Change %
-2.7%
% of All Funds
1.11%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
19
Increased
27
Reduced
18
Closed
20
Calls
$406K
Puts
–
Net Calls
+$406K
Net Calls Change
+$542K

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$6.11M
2
Ensign Peak Advisors
Ensign Peak Advisors
Utah
+$3.33M
3
BlackRock
BlackRock
New York
+$2.86M
4
WA
Wasatch Advisors
Utah
+$2.78M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$2.44M

Top Sellers

Rank Fund Capital Flow
1
BC
Boxer Capital
California
-$16.7M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$4.35M
3
Millennium Management
Millennium Management
New York
-$2.91M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$2.9M
5
Marshall Wace
Marshall Wace
United Kingdom
-$2.75M
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$58.2M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$25M -$4.35M -534,812 -12%
NI
3
Nextech Invest
Switzerland
$12.7M +$15.5M +1,910,029 New
WA
4
Wasatch Advisors
Utah
$11.8M +$2.78M +341,762 +24%
RCM
5
RA Capital Management
Massachusetts
$11.6M – – –
BlackRock
6
BlackRock
New York
$10.5M +$2.86M +351,626 +29%
Morgan Stanley
7
Morgan Stanley
New York
$9.26M +$6.11M +752,209 +118%
Vanguard Group
8
Vanguard Group
Pennsylvania
$8.73M -$2.9M -357,428 -21%
EC
9
EcoR1 Capital
California
$7.06M -$1.01M -124,700 -11%
NCM
10
Nantahala Capital Management
Connecticut
$6.7M -$1.79M -220,169 -18%
Millennium Management
11
Millennium Management
New York
$3.96M -$2.91M -358,432 -38%
WP
12
Woodline Partners
California
$3.29M +$558K +68,634 +16%
Ensign Peak Advisors
13
Ensign Peak Advisors
Utah
$2.73M +$3.33M +409,975 New
Geode Capital Management
14
Geode Capital Management
Massachusetts
$2.61M +$1.68M +207,000 +112%
Two Sigma Investments
15
Two Sigma Investments
New York
$2.61M +$1.96M +241,112 +160%
Renaissance Technologies
16
Renaissance Technologies
New York
$2.45M +$2.04M +251,400 +216%
State Street
17
State Street
Massachusetts
$2.16M +$154K +18,944 +6%
T. Rowe Price Associates
18
T. Rowe Price Associates
Maryland
$2M +$2.44M +299,674 New
D.E. Shaw & Co
19
D.E. Shaw & Co
New York
$1.67M -$4.58K -564 -0.2%
Two Sigma Advisers
20
Two Sigma Advisers
New York
$1.51M +$1.54M +189,100 +503%
Northern Trust
21
Northern Trust
Illinois
$1.2M -$47.9K -5,889 -3%
JP Morgan Chase
22
JP Morgan Chase
New York
$1.14M +$993K +122,174 +246%
Schroder Investment Management Group
23
Schroder Investment Management Group
United Kingdom
$1.07M +$40.9K +5,037 +3%
Charles Schwab
24
Charles Schwab
California
$992K +$79.9K +9,838 +7%
Citadel Advisors
25
Citadel Advisors
Florida
$623K +$155K +19,073 +26%
1
2 3 4

SPRY Hedge Fund Activity: Q4 2021 in Review

72 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in ARS Pharmaceuticals (SPRY) for Q4 2021, worth a combined $200M — down 30% from $287M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of SPRY and 19 opened new positions — a net loss of 1 holder — while 18 trimmed existing stakes and 27 added.

The largest buyer was Morgan Stanley, adding an estimated $6.11M. The largest seller was Boxer Capital, exiting entirely with an estimated $16.7M sold.

  • 72 institutional investors held ARS Pharmaceuticals (SPRY) as of Q4 2021, down from 74 in Q3 2021.
  • Funds reported $200M of ARS Pharmaceuticals stock for Q4 2021, down 30% quarter-over-quarter.
  • 19 funds opened new ARS Pharmaceuticals positions in Q4 2021 and 20 closed out, a net change of -1 holder.
  • The largest ARS Pharmaceuticals buyer in Q4 2021 was Morgan Stanley, an estimated $6.11M added.
  • The largest ARS Pharmaceuticals seller in Q4 2021 was Boxer Capital, an estimated $16.7M sold.

Based on aggregated 13F filings for Q4 2021.